Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
Cell Reports|July 29, 2022
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibitionJinyang Cai, Sheeba Jacob, Richard Kurupi, et al.
Molecular Cancer Therapeutics|June 5, 2021
Venetoclax-based Rational Combinations are Effective in Models of <i>MYCN</i>-amplified NeuroblastomaKrista M Dalton, Kateryna Krytska, Timothy L Lochmann, et al.
Nature Communications|May 18, 2019
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screeningGabriele Picco, Elisabeth D Chen, Luz Garcia Alonso, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 25, 2021
Catastrophic ATP loss underlies a metabolic combination therapy tailored for <i>MYCN</i>-amplified neuroblastomaKrista M Dalton, Timothy L Lochmann, Konstantinos V Floros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2018
The Ewing Family of Tumors Relies on BCL-2 and BCL-X<sub>L</sub> to Escape PARP Inhibitor ToxicityDaniel A R Heisey, Timothy L Lochmann, Konstantinos V Floros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2018
Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with <i>In Vivo</i> Antitumor ActivityTara L Peters, Joseph Tillotson, Alison M Yeomans, et al.
Nature Cancer|April 18, 2024
PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumorsSanju Sinha, Rahulsimham Vegesna, Sumit Mukherjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2017
Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 ExpressionTimothy L Lochmann, Konstantinos V Floros, Mitra Naseri, et al.
Pageof 11